First Trust Nasdaq Pharmaceuticals ETF (FTXH) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the First Trust Nasdaq Pharmaceuticals ETF stock forecast from 0 analysts, the average analyst target price for First Trust Nasdaq Pharmaceuticals ETF is not available over the next 12 months. First Trust Nasdaq Pharmaceuticals ETF’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of First Trust Nasdaq Pharmaceuticals ETF is Bullish , which is based on 4 positive signals and 1 negative signals. At the last closing, First Trust Nasdaq Pharmaceuticals ETF’s stock price was USD 27.50. First Trust Nasdaq Pharmaceuticals ETF’s stock price has changed by -1.20% over the past week, +1.47% over the past month and +5.04% over the last year.
No recent analyst target price found for First Trust Nasdaq Pharmaceuticals ETF
No recent average analyst rating found for First Trust Nasdaq Pharmaceuticals ETF
Company Overview First Trust Nasdaq Pharmaceuticals ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and ranking. It is non-diversified. Read Less
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liqu...Read More
Frequently Asked Questions About First Trust Nasdaq Pharmaceuticals ETF (FTXH) Stock
Stock Target Advisor's fundamental analysis for First Trust Nasdaq Pharmaceuticals ETF's stock is Bullish .
FTXH stock's dividend yield is 1.55%.
Our analysis grades FTXH stock's dividend yield at B-. This means that FTXH stock's dividend yield is above 80% of the stocks in the Health sector in the NSD exchange.
Based on this FTXH may be a good dividend stock for its sector.
Unfortunately we do not have enough data on FTXH's stock to indicate what its average analyst target is.
FTXH stock's Price/Earning ratio is 21.30.
Our analysis grades FTXH stock's Price / Earning ratio at D-. This means that FTXH stock's Price/Earning ratio is above 40% of the stocks in the Health sector in the NSD exchange.
Based on this FTXH may be fairly valued for its sector
The last closing price of FTXH's stock was USD 27.50.
The most recent market capitalization for FTXH is USD 0.02B.
Unfortunately we do not have enough analyst data on FTXH's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains First Trust Nasdaq Pharmaceuticals ETF's stock.
Sorry, we do not have any data on the number of employees for First Trust Nasdaq Pharmaceuticals ETF.
Sorry we do not have any infomation available on First Trust Nasdaq Pharmaceuticals ETF's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
What not to like
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Frequently Asked Questions About First Trust Nasdaq Pharmaceuticals ETF (FTXH) Stock
Stock Target Advisor's fundamental analysis for First Trust Nasdaq Pharmaceuticals ETF's stock is Bullish .
FTXH stock's dividend yield is 1.55%.
Our analysis grades FTXH stock's dividend yield at B-. This means that FTXH stock's dividend yield is above 80% of the stocks in the Health sector in the NSD exchange.
Based on this FTXH may be a good dividend stock for its sector.
Unfortunately we do not have enough data on FTXH's stock to indicate what its average analyst target is.
FTXH stock's Price/Earning ratio is 21.30.
Our analysis grades FTXH stock's Price / Earning ratio at D-. This means that FTXH stock's Price/Earning ratio is above 40% of the stocks in the Health sector in the NSD exchange.
Based on this FTXH may be fairly valued for its sector
The last closing price of FTXH's stock was USD 27.50.
The most recent market capitalization for FTXH is USD 0.02B.
Unfortunately we do not have enough analyst data on FTXH's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains First Trust Nasdaq Pharmaceuticals ETF's stock.
Sorry, we do not have any data on the number of employees for First Trust Nasdaq Pharmaceuticals ETF.
Sorry we do not have any infomation available on First Trust Nasdaq Pharmaceuticals ETF's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for FTXH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
